Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Net Margin (2016 - 2025)

Protalix BioTherapeutics has reported Net Margin over the past 16 years, most recently at 12.08% for Q4 2025.

  • Quarterly results put Net Margin at 12.08% for Q4 2025, down 7399.0% from a year ago — trailing twelve months through Dec 2025 was 4.06% (down 1851.0% YoY), and the annual figure for FY2025 was 3.84%, down 1829.0%.
  • Net Margin for Q4 2025 was 12.08% at Protalix BioTherapeutics, down from 13.52% in the prior quarter.
  • Over the last five years, Net Margin for PLX hit a ceiling of 61.91% in Q4 2024 and a floor of 177.18% in Q4 2023.
  • Median Net Margin over the past 5 years was 28.9% (2022), compared with a mean of 37.21%.
  • Biggest five-year swings in Net Margin: plummeted -13993bps in 2023 and later soared 23908bps in 2024.
  • Protalix BioTherapeutics' Net Margin stood at 77.37% in 2021, then soared by 52bps to 37.25% in 2022, then plummeted by -376bps to 177.18% in 2023, then surged by 135bps to 61.91% in 2024, then plummeted by -120bps to 12.08% in 2025.
  • The last three reported values for Net Margin were 12.08% (Q4 2025), 13.52% (Q3 2025), and 1.05% (Q2 2025) per Business Quant data.